Literature DB >> 23079771

Olfactory dysfunction in fragile X tremor ataxia syndrome.

Jorge L Juncos1, Joash T Lazarus, Julia Rohr, Emily G Allen, Lisa Shubeck, Debra Hamilton, Gloria Novak, Stephanie L Sherman.   

Abstract

INTRODUCTION: We investigated olfactory defects in fragile X-associated tremor/ataxia syndrome (FXTAS), a finding reported on in other neurodegenerative disorders with clinical features that overlap those of FXTAS.
METHODS: We measured olfactory identification capacity in 41 FMR1 premutation carriers and 42 controls using the University of Pennsylvania Smell Identification Test (UPSIT). Carriers received neurologic evaluations using motor rating scales for tremor, ataxia, and parkinsonism. Cognitive function was measured using the Montreal Cognitive Assessment test.
RESULTS: Frequency of olfactory defects was higher in carriers, compared to controls (61% versus 29%; P = 0.003). There was no statistically significant group difference in severity of olfaction defects, after accounting for differences in age, and in rates of head injury and smoking. However, both the frequency (odds ratio = 3.9; 95% confidence interval: 0.81-19.1) and severity (28.6 versus 33.4; P = 0.01) of these defects were greater in cognitively impaired, compared to cognitively intact, carriers. There was no correlation between UPSIT scores and the above-mentioned motor rating scales.
CONCLUSIONS: FMR1 premutation carriers are susceptible to olfactory identification defects. The severity of these defects is comparable to that reported in hereditary ataxias, but less than that in PD and Alzheimer's disease. This concurrence across neurodegenerative disorders suggests a shared system vulnerability that correlates with, but is not limited to, cognitive impairment, because it is also found in cognitively intact carriers. These results need to be corroborated in a larger prospective study of FMR1 premutation carriers that extends beyond olfactory identification to include measures of smell thresholds.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 23079771      PMCID: PMC3696490          DOI: 10.1002/mds.25043

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  Olfaction and neurodegeneration in HD.

Authors:  Fernando A Barrios; Leopoldo Gonzalez; Rafael Favila; Maria E Alonso; Perla M Salgado; Rosalinda Diaz; Juan Fernandez-Ruiz
Journal:  Neuroreport       Date:  2007-01-08       Impact factor: 1.837

Review 2.  The olfactory system and its disorders.

Authors:  Richard L Doty
Journal:  Semin Neurol       Date:  2009-02-12       Impact factor: 3.420

3.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

Review 4.  Using olfaction to study memory.

Authors:  H Eichenbaum
Journal:  Ann N Y Acad Sci       Date:  1998-11-30       Impact factor: 5.691

5.  Increased T2 signal in the middle cerebellar peduncles on MRI is not specific for fragile X premutation syndrome.

Authors:  Elsdon Storey; Phiroz Billimoria
Journal:  J Clin Neurosci       Date:  2005-01       Impact factor: 1.961

6.  Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases.

Authors:  R I Mesholam; P J Moberg; R N Mahr; R L Doty
Journal:  Arch Neurol       Date:  1998-01

7.  Neuropathic features in fragile X premutation carriers.

Authors:  Elizabeth Berry-Kravis; Christopher G Goetz; Maureen A Leehey; Randi J Hagerman; Lin Zhang; Lexin Li; Danh Nguyen; Deborah A Hall; Nicole Tartaglia; Jennifer Cogswell; Flora Tassone; Paul J Hagerman
Journal:  Am J Med Genet A       Date:  2007-01-01       Impact factor: 2.802

Review 8.  Olfactory dysfunction as a diagnostic marker for Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Heinz Reichmann
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

Review 9.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

10.  Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity.

Authors:  Kelvin L Chou; Nicolaas I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2009-03-28       Impact factor: 4.891

View more
  8 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

2.  Fragile X mental retardation protein regulates olfactory sensitivity but not odorant discrimination.

Authors:  Arielle Schilit Nitenson; Emily E Stackpole; Torrey L S Truszkowski; Maellie Midroit; Justin R Fallon; Kevin G Bath
Journal:  Chem Senses       Date:  2015-04-27       Impact factor: 3.160

Review 3.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 4.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

5.  Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Authors:  Jonathan Polussa; Andrea Schneider; Randi Hagerman
Journal:  Brain Disord Ther       Date:  2014

Review 6.  Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications.

Authors:  Ana Maria Cabal-Herrera; Nattaporn Tassanakijpanich; Maria Jimena Salcedo-Arellano; Randi J Hagerman
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

7.  Olfactory loss is a predisposing factor for depression, while olfactory enrichment is an effective treatment for depression.

Authors:  Michael Leon; Cynthia C Woo
Journal:  Front Neurosci       Date:  2022-09-28       Impact factor: 5.152

Review 8.  A systematic-review of olfactory deficits in neurodevelopmental disorders: From mouse to human.

Authors:  Ariel M Lyons-Warren; Isabella Herman; Patrick J Hunt; Benjamin R Arenkiel
Journal:  Neurosci Biobehav Rev       Date:  2021-02-18       Impact factor: 9.052

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.